Zobrazeno 1 - 10
of 372
pro vyhledávání: '"Cowan, Jacob"'
Publikováno v:
In Biological Conservation August 2024 296
Publikováno v:
Qualitative Sociology Review. 19(2):74-91
Externí odkaz:
https://www.ceeol.com/search/article-detail?id=1121668
Publikováno v:
In Leukemia Research November 2020 98
Autor:
Fonné-Pfister, R., Chemla, P., Ward, E., Girardet, M., Kreuz, K. E., Honzatko, R. B., Fromm, H. J., Grütter, M. G., Cowan-Jacob, S. W.
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America, 1996 Sep 01. 93(18), 9431-9436.
Externí odkaz:
https://www.jstor.org/stable/39727
Autor:
Mingxing Teng, Marlise R. Luskin, Sandra W. Cowan-Jacob, Qiang Ding, Doriano Fabbro, Nathanael S. Gray
Publikováno v:
Journal of Medicinal Chemistry. 65:7581-7594
Autor:
Brian J. Druker, Michael W.N. Deininger, Michael C. Heinrich, Francis Y. Lee, Sandra W. Cowan-Jacob, Jürgen Mestan, Paul W. Manley, Taiping Jia, Eric P. Stoffregen, Denise K. Walters, Thomas O'Hare
Supplementary Figure 1 from In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce7c50e8252c29432fba9d680c092363
https://doi.org/10.1158/0008-5472.22363796
https://doi.org/10.1158/0008-5472.22363796
Autor:
Brian J. Druker, Michael W.N. Deininger, Michael C. Heinrich, Francis Y. Lee, Sandra W. Cowan-Jacob, Jürgen Mestan, Paul W. Manley, Taiping Jia, Eric P. Stoffregen, Denise K. Walters, Thomas O'Hare
Supplementary Figure 2 from In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d470f271be312223f11ea55486fd7f1
https://doi.org/10.1158/0008-5472.22363793
https://doi.org/10.1158/0008-5472.22363793
Autor:
Brian J. Druker, Michael W.N. Deininger, Michael C. Heinrich, Francis Y. Lee, Sandra W. Cowan-Jacob, Jürgen Mestan, Paul W. Manley, Taiping Jia, Eric P. Stoffregen, Denise K. Walters, Thomas O'Hare
Imatinib, a Bcr-Abl tyrosine kinase inhibitor, is a highly effective therapy for patients with chronic myelogenous leukemia (CML). Despite durable responses in most chronic phase patients, relapses have been observed and are much more prevalent in pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42fd1a2e5cff20d17b66aaeb1d9f2594
https://doi.org/10.1158/0008-5472.c.6493898
https://doi.org/10.1158/0008-5472.c.6493898
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Wolfgang Jahnke, Johannes Paladini, Judith M. Habazettl, Andrea Wiget, Alice Loo, Sandra W. Cowan Jacob, Stephan Grzesiek, Paul W. Manley
Publikováno v:
Angewandte Chemie. 134
Soellner published on the interplay between allosteric and adenosine triphosphate (ATP)-competitive inhibitors of ABL kinase, showing that the latter preferably binds to different conformational states of ABL compared to allosteric agents that specif